The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
Shah et al.
, The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
, JNCI Cancer Spectrum, doi:10.1093/jncics/pkac035
Retrospective 465 prostate cancer patients, showing no significant difference in COVID-19 outcomes with ADT.
risk of death, 16.0% higher, HR 1.16, p = 0.59, treatment 148, control 317.
risk of mechanical ventilation, 19.0% lower, HR 0.81, p = 0.73, treatment 148, control 317.
risk of severe case, 3.0% higher, HR 1.03, p = 0.91, treatment 148, control 317.
risk of hospitalization, 4.0% lower, HR 0.96, p = 0.90, treatment 148, control 317.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shah et al., 12 May 2022, retrospective, USA, peer-reviewed, median age 71.0, 22 authors, study period 1 March, 2020 - 31 May, 2020.
Abstract: JNCI Cancer Spectrum (2022) 6(3): pkac035
First published online May 12, 2022
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in
Men With Prostate Cancer
,1,2,‡ Vaibhav G. Patel, MD
, Qian Qin, MD, George Mellgard, BA
Jones T. Nauseef, MD
, Himanshu Joshi, PhD
, David A. Green, MD, Panagiotis J. Vlachostergios, MD, PhD
Franklin Huang, MD, Bobby Liaw, MD, Scott Tagawa, MD
William K. Oh, MD
,3 Luis Pina, MD,4
,4 Emily Lin, MD,5 Benjamin A. Gartrell, MD,5 Victor Adorno Febles, MD
Jessica E. Hawley, MD
David R. Wise, MD
,3,‡ Xiaobo Zhong, DrPD
, Philip Kantoff, MD,
,2 Daniel H. Kwon, MD,7
Michael J. Morris, MD,1,2
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Department of Medicine, Weill Cornell Medical Center, New York, NY, USA;
Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 4Department of Medicine, Columbia University Medical Center, New York, NY,
USA; 5Department of Medicine, Montefiore Center for Cancer Care, Bronx, NY, USA; 6Department of Medicine, NYU Langone Medical Center, New York, NY, USA and
Department of Medicine, University of California, San Francisco, CA, USA
These authors contributed equally.
*Correspondence to: William K. Oh, MD, Clinical Professor of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine
at Mount Sinai, One Gustave L. Levy Pl, Box 1128, New York, NY 10029, USA (e-mail: firstname.lastname@example.org).
Background: TMPRSS2, a cell surface protease regulated by androgens and commonly upregulated in prostate cancer (PCa), is
a necessary component for SARS-CoV-2 viral entry into respiratory epithelial cells. Previous reports suggested a lower risk of
SARS-CoV-2 among PCa patients on androgen deprivation therapy (ADT). However, the impact of ADT on severe COVID-19 illness is poorly understood. Methods: We performed a multicenter study across 7 US medical centers and evaluated patients
with PCa and SARS-CoV-2 detected by polymerase-chain-reaction between March 1, 2020, and May 31, 2020. PCa patients
were considered on ADT if they had received appropriate ADT treatment within 6 months of COVID-19 diagnosis. We used
multivariable logistic and Cox proportional-hazard regression models for analysis. All statistical tests were 2-sided. Results:
We identified 465 PCa patients (median age ¼ 71 years) with a median follow-up of 60 days. Age, body mass index, cardiovascular comorbidity, and PCa clinical disease state adjusted overall survival (hazard ratio [HR] ¼ 1.16, 95% confidence interval
[CI] ¼ 0.68 to 1.98, P ¼ .59), hospitalization status (HR ¼ 0.96, 95% CI ¼ 0.52 to 1.77, P ¼ .90), supplemental oxygenation (HR 1.14,
95% CI ¼ 0.66 to 1.99, P ¼ .64), and use of mechanical ventilation (HR ¼ 0.81, 95% CI ¼ 0.25 to 2.66, P ¼ .73) were similar between
ADT and non-ADT cohorts. Similarly, the addition of androgen receptor–directed therapy within 30 days of COVID-19 diagnosis to ADT vs ADT alone did not statistically significantly affect overall survival (androgen receptor–directed therapy: HR ¼
1.27, 95% CI ¼ 0.69 to 2.32, P ¼ .44). Conclusions: In this retrospective cohort of PCa patients, the use of ADT was not
demonstrated to influence severe COVID-19 outcomes, as defined by hospitalization, supplemental oxygen use, or death. Age
70 years and older was statistically..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.